Drug Approval | March 27, 2024
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
The drug will target specific genetic mutations prevalent in certain types of cancers
It is the first autotaxin inhibitor to be investigated in cancer patients
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Subscribe To Our Newsletter & Stay Updated
